Literature DB >> 15582192

Absence of toxic effects in F344/N rats and B6C3F1 mice following subchronic administration of chromium picolinate monohydrate.

M C Rhodes1, C D Hébert, R A Herbert, E J Morinello, J H Roycroft, G S Travlos, K M Abdo.   

Abstract

Chromium picolinate monohydrate (CPM) is a synthetic compound heavily marketed to consumers in the United States for use as a dietary supplement for muscle building and weight loss. The National Toxicology Program (NTP) tested the toxicity of this compound based on the potential for widespread consumer exposure and lack of information about its toxicity. Groups of 10 male and 10 female F344/N rats and B6C3F(1) mice were exposed to 0, 80, 240, 2000, 10,000, or 50,000 ppm CPM in feed for 13 weeks. CPM administration produced no effect on body weight gain or survival of rats or mice. Organ weights and organ/body weight ratios in exposed animals were generally unaffected by CPM. No compound-related changes in hematology and clinical chemistry parameters were observed. There were no histopathological lesions attributed to CPM in rats or mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582192     DOI: 10.1016/j.fct.2004.08.006

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  9 in total

1.  Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.

Authors:  Kristina Yeghiazaryan; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2012-10

2.  Chromium-picolinate therapy in diabetes care: molecular and subcellular profiling revealed a necessity for individual outcome prediction, personalised treatment algorithms and new guidelines.

Authors:  Kristina Yeghiazaryan; Viktoriya Peeva; Aparna Shenoy; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2011-04

3.  Chromium supplementation improves glucose tolerance in diabetic Goto-Kakizaki rats.

Authors:  Aicha Abdourahman; John G Edwards
Journal:  IUBMB Life       Date:  2008-08       Impact factor: 3.885

4.  Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro.

Authors:  Rituparna Ganguly; Amy M Wen; Ashley B Myer; Tori Czech; Soumyadip Sahu; Nicole F Steinmetz; Priya Raman
Journal:  Nanoscale       Date:  2016-03-28       Impact factor: 7.790

5.  Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years.

Authors:  M D Stout; A Nyska; B J Collins; K L Witt; G E Kissling; D E Malarkey; M J Hooth
Journal:  Food Chem Toxicol       Date:  2009-01-08       Impact factor: 6.023

6.  Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE-/- mice.

Authors:  Rituparna Ganguly; Soumyadip Sahu; Vahagn Ohanyan; Rebecca Haney; Ronaldo J Chavez; Shivani Shah; Siri Yalamanchili; Priya Raman
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

7.  Estimated intestinal absorption of phosphorus and its deposition in chosen tissues, bones and feathers of chickens receiving chromium picolinate or chromium nanoparticles in diet.

Authors:  Anna Stępniowska; Krzysztof Tutaj; Aleksandra Drażbo; Krzysztof Kozłowski; Katarzyna Ognik; Jan Jankowski
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

8.  Opinion controversy to chromium picolinate therapy's safety and efficacy: ignoring 'anecdotes' of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan
Journal:  EPMA J       Date:  2012-10-07       Impact factor: 6.543

9.  miR-375 and miR-30d in the effect of chromium-containing Chinese medicine moderating glucose metabolism.

Authors:  Qian Zhang; Xinhua Xiao; Ming Li; Wenhui Li; Miao Yu; Huabing Zhang; Fan Ping; Zhixin Wang; Jia Zheng; HongDing Xiang
Journal:  J Diabetes Res       Date:  2014-04-09       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.